Choice of Acid Suppressant Therapy and Long-Term Graft Outcomes After Kidney Transplantation.
histamine-2 receptor antagonist
kidney transplantation
proton pump inhibitor
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
11
10
2020
medline:
4
9
2021
entrez:
10
10
2020
Statut:
ppublish
Résumé
The purpose of this study was to comprehensively evaluate the long-term adverse effects of proton pump inhibitors (PPIs) compared with histamine-2 receptor antagonists (H2RAs) in kidney transplant recipients. This retrospective cohort compared 582 patients treated with PPI with 705 patients treated with H2RA and evaluated adverse effects throughout their course of acid suppressant therapy to a maximum of nine years posttransplant. The primary outcome of interest was renal function at 1 year posttransplant; secondary outcomes included renal function at 30 days, 3, 5, and 9 years posttransplant as well as rejection, electrolyte and laboratory abnormalities, osteoporosis, pneumonia, and Clostridium difficile infections. Renal function did not significantly differ at any timepoint posttransplant. Rejection rates and Clostridium difficile infections were similar between groups; osteoporosis and pneumonia rates were numerically higher in the PPI treated arm but did not reach statistical significance. Proton pump inhibitor (PPI) treated patients were more likely to experience hypomagnesemia requiring supplementation. High dose PPI treated patients had significantly higher rates of pneumonia and osteoporosis compared with H2RA treated patients. Patients were maintained on PPI therapy for an average of 5 years and H2RA therapy for 3 years posttransplant, the majority without a clear indication for therapy. There was no difference in renal function, rejection, or graft loss between PPI and H2RA treated patients. The majority of patients were maintained on PPI therapy for several years posttransplant without a clear indication; critical evaluation of ongoing need for acid suppressant therapy in the posttransplant course should be an area of future focus.
Substances chimiques
Histamine H2 Antagonists
0
Proton Pump Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1082-1088Informations de copyright
© 2020 Pharmacotherapy Publications, Inc.
Références
Hardinger KL, Brennan DC, Lowell J, et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004;17(10):609-16.
Riskalla MM, Somers EC, Fatica RA, et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003;30(7):1508.
Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983;309(1):21-4.
Sierra F, Suarez M, Rey M, et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Ailment Pharmacol Ther 2007;26:545-53.
Blank ML, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int 2014;86(4):837-44.
Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol 2016;17:112.
Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant 2018;33:331-42.
Lazarus B, Chen Y, Wilson FP. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;176(2):238-46.
Makunts T, Cohen IV, Awdishu L, et al. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019;9(1):2282.
Binnetoğlu E, Akbal E, Şen H, et al. Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding. Platelets 2015;1:10-2.
Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83(4):251-9.
Patel KS, Stephany BR, Barnes JF, et al. Renal transplant acute rejection with lower mycophenolate mofetil dosing and proton pump inhibitors or histamine-2 receptor antagonists. Pharmacotherapy 2017;37(12):1507-15.
van Boekel GAJ, Kerkhofs CHH, van de Logt F, et al. Proton pump inhibitors do not increase the risk of acute rejection. Neth J Med 2014;72(2):86-90.
Knorr JP, Sjeime M, Braitman LE, et al. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation 2014;97:518-24.
Boonpheng B, Thongprayoon C, Bathini T, et al. Proton pump inhibitors and adverse effects in kidney transplant recipients: a meta-analysis. World J Transplant 2019;9(2):35-47.
Sunderland A, Russ G, Sullustio B, et al. Effect of proton-pump inhibitor pantoprazole on mycophenolic acid exposure in kidney and liver transplant recipients (IMPACT study): a randomized trial. Nephrol Dial Transplant 2020;35(6):1060-70.
Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol 2012;52(8):1265-72.
Kipp G, Dancsecs K, Lapping A. Proton-pump inhibitor utilization is associated with higher rates of Clostridium difficile infection and hypomagnesemia after kidney transplant. Am J Transplant 2017;17(suppl 3).
Douwes RM, Gomes-Neto AW, Schutten JC, et al. Proton-pump inhibitors and hypomagnesaemia in kidney transplant recipients. J Clin Med 2019;8(12):e2162.
Gomes-Neto A, Douwes R, Eisenga M, et al. Use of proton-pump inhibitors is associated with lower magnesium and iron status and excess mortality in renal transplant recipients. Am J Transplant 2018;18:300-1.
Douwes RM, Gomes-Neto AW, Eisenga MF, et al. Chronic use of proton-pump inhibitors and iron status in renal transplant recipients. J Clin Med 2019;8(9):e1382.
Flothow DJG, Suwelack B, Pavenstädt H, et al. The effect of proton pump inhibitor use on renal function in kidney transplanted patients. J Clin Med 2020;9(1):e258.
Rouse GE, Hardinger K, Tsapepas D, et al. A comparison of histamine receptor antagonists versus proton pump inhibitor gastrointestinal ulcer prophylaxis in kidney transplant recipients. Prog Transplant 2017;27(1):4-9.
Lyu B, Jorgenson M, Hansen KE, et al. Proton pump inhibitors, but not H2 receptor antagonists, are associated with incident fractures among kidney transplant recipients. Transplantation 2020. https://doi.org/10.1097/TP.0000000000003178
Uludag O, Mirioglu S, Dirim A, et al. Effects of proton pump inhibitors on kidney transplant recipients. Nephrol Dial Transplant 2017;32(suppl 3).
Kamal F, Khan MA, Molnar MZ, et al. The association between proton pump inhibitor use with acute kidney injury and chronic kidney disease. J Clin Gastroenterol 2018;52:468-76.
Rodriguez-Poncelas A, Barcelo MA, Saez M, et al. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS One 2018;13(10):e0204231.
Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296(24):2947-53.
Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 2011;9(3):257-67.
Leheij R, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292(16):1955-60.
Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355(19):1967-77.
Curran M, Noble S. Valganciclovir. Drugs 2001;61(8):1145-50.
Navaneethan SD, Sankarasubbaiyan S, Gross MD, et al. Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc 2006;38(5):1320-2.